SAT0350 Bone mineral density in lupus erythematosus women 1 year after rituximab therapy. (23rd January 2014)

• Record Type: Journal Article
• Authors: Garcia-Carrasco, M.; Mendoza-Pinto, C.; Etchegaray-Morales, I.; Jimenez-Hernandez, C.; Rodriguez-Gallego, A.B.; Briones-Rojas, R.; Ordoñez-Andrade, E.; Mendez-Martinez, S.; Aguilar-Cuenca, J.E.; Cervera, R.
• Is Part Of: Annals of the rheumatic diseases. Volume 71(2012)Supplement 3
• Page Start: 590
• Page End: 591
• Publication Date: 2014-01-23
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2012-eular.3296
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Patients with systemic lupus erythematosus (SLE) have a higher prevalence of osteoporosis and low bone mineral density (BMD) compared with the general population. Rituximab, a CD20 depleting antibody, has been administrated in patients with refractory SLE. However, to date, its influence on bone mineral density (BMD) in women with SLE is unknown. Objectives: The aim of this prospective study was to assess the effects of rituximab treatment on BMD of the lumbar and femoral neck in women with SLE. Methods: Thirty active female SLE patients treated with rituximab were compared with control SLE women not treated with rituximab. BMD of the femoral neck and lumbar spine was measured using dual energy x-ray absorptiometry ( Hologic, Inc.) before initiating biologic therapy and after one year. The Student's t test was used to detect differences in BMD in the rituximab and control groups. Analysis of covariance was used to examine for confounders including disease duration, disease activity and age. Results: 76 patients were studied. 30 patients received rituximab and 46 controls received conventional treatment. In the rituximab group, the mexSLEDAI score was 3.4±1.8 at baseline and 0.8±1.5 (p=0.001) after one year of rituximab. There were 5 non-responders. Patients receiving rituximab were significantly younger and had significantly higher activity scores (mexSLEDAI) than controls. Baseline BMD measurements were higher in the rituximab group but the only significant difference was at the lumbar spine. BMD was reduced from 0.980±0.130 g/cm 2 to 0.809±0.139 g/cm 2 (-17.4%; p=0.001) at the femoral neck and from 1.062±0.137g/cm 2 to 0.893±0.194 g/cm 2 (-15.8%; p=0.001) at the lumbar spine in the rituximab group after 12 months of rituximab. BMD was reduced from 0.914±0.193 g/cm 2 to 0.790±0.135 g/cm 2 (-13.6%; p=0.001) at the femoral neck and 0.926±0.128 g/cm 2 to 0.867±0.139 g/cm 2 (-6.2%; p=0.09) at the lumbar spine in controls after 12 months of treatment. Variables associated with a low BMD included age, menopausal status and steroid dose. A logistic regression model was used to analyze the specific effect of rituximab within the context of these possible confounding factors and showed that only postmenopausal status was associated with BMD loss (p=0.03). However, BMD loss was higher in postmenopausal rituximab patients than in postmenopausal controls (0.324±0.128 g/cm 2 vs 0.138±0.099 g/cm 2 ). Conclusions: After one year of follow up, patients had lower BMD at both the femoral neck and lumbar spine, but the loss was greater in patients receiving rituximab than in patients receiving conventional treatment, and in postmenopausal women. Although further studies are required to confirm this relationship, postmenopausal candidates for rituximab should be evaluated closely to prevent further BMD loss. Disclosure of Interest: None Declared